We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Puretech Health Plc | PRTC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.20 | -0.13% | 150.20 | 12:35:09 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 148.00 | 148.00 | 152.40 | 150.20 | 150.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 30/12/2024 10:17 by yasx Broker notes should generally ve ignored, but PRTC looks very cheap down here around 150p. |
Posted at 18/12/2024 12:37 by takeiteasy pretty clear then i think from this link and the PRTC presentation...have to believe despite DT in USA this can move.... |
Posted at 16/12/2024 19:48 by mirabeau thanks to TOB : |
Posted at 16/12/2024 07:46 by rimau1 My understanding is that its a quick turnaround to phase 3 because its a version of an existing approved product that PRTC make tweaks to for example one such tweak is to improve tolerability. This is our USP.The last 2 announcements are pretty much as bullish as you could hope for IMO |
Posted at 16/12/2024 07:17 by takeiteasy The Oak bloke again...If you believe LYT-100 will succeed, that 2% royalties will be based on $2.5bn for 15 years (undiscounted) .... |
Posted at 05/12/2024 08:13 by peterm35 Assuming PRTC get the LYT100 and 200 study details out in Q4 as suggested, then we only have 13 working days left till Christmas, can't imagine they will publish between Xmas and NY. Really not long to wait now. |
Posted at 23/11/2024 10:43 by takeiteasy "PureTech Health certainly appears significantly undervalued. However, for a traditional investor looking at earnings multiples or dividend yield, valuing PureTech is tricky. As with many biotech companies, there is little revenue and substantial annual losses, and it's unclear how an investor will realise this value. In addition, the recent share tender offer left a perceived overhang, and the shares have been heavily sold off."I would like to think the firm is addressing this in two specific areas that I can see. Ensure they get a share of recurring sales income from drug developments they sell to big pharma alongside having entities within the group launced via IPOs that have a public rather than private status so analysts can impute direct market values for PRTC's retained % holding rather than rely on estimates. Given the scale of undervaluation has been shown by a number of analysts to be so great any hint now of a plan or path to addressing this MAY be enough for a rethink of the opportunity (choose words carefully here) I would like us to become more like the BG USA trust model of a public and private equity split within the portfolio :) nai etc |
Posted at 30/10/2024 14:07 by takeiteasy Seaport announcements a master stroke in my book i.e. ensure a well over subscribed funding round and then follow up to the IIs with the message if you want more of the Seaport exposure without having to wait for the next funding round then buy some/more PRTC ... and heh presto PRTC price shoots up ..lols...:)nai etc |
Posted at 25/10/2024 08:33 by peterm35 Hi take it easy, I’ve actually read both of Oak Blokes write ups, they actually inspired me to do it. I’ve enjoyed them both, he’s been very thorough and it’s good that people are starting to notice PRTC. He valued Seaport at the total raised in the 2 fundraises ($325m). I think that’s a bit conservative if you consider that no Venture Capitalist or Investment house is going to invest in a company if it’s valued for no growth, there needs to be significant upside potential for the risk they take on. I think my own limited valuation is probably short of the mark too, but better to be pessimistic than optimistic.I believe, and Oak Bloke touches on it too, that there’s a great deal riding on LYT100. A decent Phase 2b there and we should, fingers crossed, be off to the races. |
Posted at 24/10/2024 10:35 by edwardt BMS paid $14bn for consensus sales that total $17bn out ten years. only a 20% market share equates to $4bn sales at 20k a pop. either BMS are stupid or consensus sales are way undercooked. i still get to £300m of value to prtc using a 10% discount rate on consensus sales. bonkers imho. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
